Overview

Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
If tigecycline clearance increases with body size then serum exposure values will be lower in obese class III compared to normal weight subjects because exposure changes inversely with clearance when the dose is fixed without regard to weight.
Phase:
Phase 4
Details
Lead Sponsor:
Manjunath Prakash Pai
Collaborator:
Pfizer
Treatments:
Minocycline
Tigecycline